Skip to main content
OpenTrials
Completed

NCT Number: NCT05585021

Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children

This is a randomized controlled trial, to evaluate the effect of WONDERLAB Probiotic Compound Powder on improving immunity of preschool children

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wenan Wang

Jinhua, Zhejiang, 321013, China

About this study

The community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group.

First entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preschool children, male or female, 5 to 6 years old;
  • Those with weak constitution and easy to get sick:

One of them can be satisfied:

AGet cold ≥ 3 times a year B Bronchitis or pneumonia ≥2 times per year C Rotavirus diarrhea ≥1 time per year

  • During the trial, participants agree not to take any drugs, supplements, or other dairy products containing probiotics;
  • During the trial, participants agree not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt drinks;
  • Willing to refrain from participating in other interventional clinical studies during the trial period;
  • Be able to fully understand the nature, purpose, benefits and possible risks and side effects of the research;
  • Willing to obey all test requirements and procedures;
  • Informed consent signed by parents or legal guardians.

Exclusion criteria

  • Subject who is in the treatment of gastrointestinal diseases;
  • Subject who has lactose intolerance;
  • The subjects are currently suffering from other organic diseases that affect intestinal function, such as history of gastrointestinal resection, colonic or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.;
  • Subjects have any of the following medical histories or clinically diagnosed diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;
  • According to the judgment of the researchers, frequent use of drugs that may affect gastrointestinal function or the immune system;
  • Subjects who took laxatives or other digestive aids 2 weeks before the start of the study;
  • Consumed dairy products or other foods containing prebiotics/bacteria within 10 days before the start of the study;
  • PI believes that volunteers cannot fully cooperate with the trial arrangement.

Treatment and study plan

Wonderlab Kids instant probiotics

Dietary Supplement

During study intervention, subjects are required to take the randomly assigned product based on the randomization list.

Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period.

Instant probiotic placebo

Dietary Supplement

Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.

Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.

1 bottle a day. Lasting for 24 weeks intervention period.

Primary outcomes

  1. Rotavirus diarrhea Testing at baseline

    Time frame: baseline(day 0)

    Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 12 month

  2. Rotavirus diarrhea Testing at endpoint

    Time frame: endpoint( day 168)

    Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 168 days

  3. Infection of the upper respiratory tract at baseline

    Time frame: baseline(day 0)

    Drug records of upper respiratory tract infection within past 12 months.

  4. Infection of the upper respiratory tract at endpoint

    Time frame: endpoint ( day 168)

    Drug records of upper respiratory tract infection within past 168 days.

Secondary outcomes

  1. Bristol Stool Chart

    Time frame: baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)

    To evaluate samples of human feces based on the shape and consistency of the stool.

  2. Faeces

    Time frame: baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)

    sIgA 、16sRNA、SCFA、Fecal calprotectin

  3. Saliva

    Time frame: baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)

    sIgA testing

  4. Pittsburgh sleep quality index

    Time frame: baseline(day 0)/interim ( day 84)/endpoint( day 168)

    18 items comprise 7 components, each of which is scored according to o~3 grade. The cumulative score of each component is the total score of PSQI, with a total score range of 0~2l. The higher the score, the worse the sleep quality.

Sponsors and collaborators

Lead sponsor

Shenzhen Precision Health Food Technology Co. Ltd.,

Other Gov

Registry information

Official study title

A Clinical Study on The Effect of Probiotic Compound Powder (WONDERLAB) on The Immunity Improvement of Preschool Children (RCT)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 18, 2022
Registry last updated
Nov 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.